Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatiti
Go back to Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatiti| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1098.57 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1098.57 | 52 Week High | $88.16 | |||
| Open | $1098.57 | 52 Week Low | $67.88 | |||
| Day High | $1098.57 | P/E | 254.30 | |||
| Day Low | $1098.57 | EPS | $4.32 | |||
| Volume | 6,348 | |||||
